ecrin-mdr-crcClinical2023IPD Sharing (as of September 2023): NoMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2752431United States3NRAS MutationKRAS MutationOnvansertibBevacizumabFOLFIRIECRIN MDRActive, not recruitingfalseStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationThe primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.2023-03-152752431NCT05593328